Laborotary of Vaccines and Immunotherapeutics, Institute of Bioscience, Universiti Putra Malaysia, Serdang, 43400, Selangor, Malaysia.
UKM Molecular Biology Institute (UMBI), UKM Medical Centre, Jalan Yaa'cob Latiff, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.
Sci Rep. 2019 Feb 6;9(1):1514. doi: 10.1038/s41598-018-37796-w.
Eupatorin has been reported with in vitro cytotoxic effect on several human cancer cells. However, reports on the mode of action and detail mechanism of eupatorin in vitro in breast cancer disease are limited. Hence, eupatorin's effect on the human breast carcinoma cell line MCF-7 and MDA-MB-231 was investigated. MTT assay showed that eupatorin had cytotoxic effects on MCF-7 and MDA-MB-231 cells but was non-toxic to the normal cells of MCF-10a in a time-dose dependent manner. At 24 h, the eupatorin showed mild cytotoxicity on both MCF-7 and MDA-MB-231 cells with IC values higher than 20 μg/mL. After 48 h, eupatorin at 5 μg/mL inhibited the proliferation of MCF-7 and MDA-MB-231 cells by 50% while the IC of MCF-10a was significantly (p < 0.05) high with 30 μg/mL. The concentration of eupatorin at 5 μg/mL induced apoptosis mainly through intrinsic pathway by facilitating higher fold of caspase 9 compared to caspase 8 at 48 h. The cell cycle profile also showed that eupatorin (5 μg/mL) exerted anti-proliferation activity with the cell cycle arrest of MCF-7 and MDA-MB-231 cells at sub Gθ/G1 in a time-dependent manner. In addition, wound healing assay showed an incomplete wound closure of scratched MDA-MB-231 cells, and more than 60% of the MDA-MB-231 cells were prevented to migrate and invade the membrane in the Boyden chamber after 24 h. Eupatorin also inhibited angiogenic sprouting of new blood vessels in ex vivo mouse aorta ring assay. In gene expression assay, eupatorin up-regulated pro-apoptotic genes such as Bak1, HIF1A, Bax, Bad, cytochrome c and SMAC/Diablo and blocked the Phospho-Akt pathway. In conclusion, eupatorin is a potent candidate to induce apoptosis and concurrently inhibit the invasion, migration and angiogenesis of MDA-MB-231 and MCF-7 cells through inhibition of Phospho-Akt pathway and cell cycle blockade.
瑞香素已被报道具有体外细胞毒性作用,可杀伤几种人类癌细胞。然而,有关瑞香素在乳腺癌疾病中的作用模式和详细机制的报道有限。因此,研究了瑞香素对人乳腺癌细胞系 MCF-7 和 MDA-MB-231 的影响。MTT 检测表明,瑞香素对 MCF-7 和 MDA-MB-231 细胞具有细胞毒性作用,但在时间-剂量依赖性方式下对 MCF-10a 的正常细胞无毒性。在 24 小时时,瑞香素对 MCF-7 和 MDA-MB-231 细胞表现出轻度细胞毒性,IC 值均高于 20μg/ml。48 小时后,5μg/ml 的瑞香素可使 MCF-7 和 MDA-MB-231 细胞的增殖抑制 50%,而 MCF-10a 的 IC 值明显(p<0.05)高,为 30μg/ml。浓度为 5μg/ml 的瑞香素通过促进 caspase 9 的倍数高于 caspase 8,主要通过内在途径诱导凋亡。细胞周期谱也表明,瑞香素(5μg/ml)通过使 MCF-7 和 MDA-MB-231 细胞在亚 Gθ/G1 期的细胞周期停滞,发挥抗增殖活性。此外,划痕愈合试验显示,划痕 MDA-MB-231 细胞的不完全伤口闭合,并且在 24 小时后,超过 60%的 MDA-MB-231 细胞被阻止迁移和侵袭膜。瑞香素还抑制了体外小鼠主动脉环试验中新生血管的血管生成发芽。在基因表达试验中,瑞香素上调促凋亡基因,如 Bak1、HIF1A、Bax、Bad、细胞色素 c 和 SMAC/ Diablo,并阻断磷酸化 Akt 途径。总之,瑞香素是一种有效的候选药物,可通过抑制磷酸化 Akt 途径和细胞周期阻滞,诱导 MDA-MB-231 和 MCF-7 细胞凋亡,并同时抑制其侵袭、迁移和血管生成。